210 related articles for article (PubMed ID: 18230056)
1. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
Poulakou G; Giamarellou H
Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056
[TBL] [Abstract][Full Text] [Related]
2. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
Das B; Sarkar C; Schachter J
Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
[TBL] [Abstract][Full Text] [Related]
3. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
4. Oritavancin: a new avenue for resistant Gram-positive bacteria.
Mercier RC; Hrebickova L
Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
[TBL] [Abstract][Full Text] [Related]
5. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
Crandon J; Nicolau DP
Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390
[TBL] [Abstract][Full Text] [Related]
6. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
7. Oritavancin: a long-acting antibacterial lipoglycopeptide.
Kaasch AJ; Seifert H
Future Microbiol; 2016 Jul; 11():843-55. PubMed ID: 27161039
[TBL] [Abstract][Full Text] [Related]
8. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
Cornaglia G; Rossolini GM
Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
[TBL] [Abstract][Full Text] [Related]
9. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
Bouza E; Burillo A
Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040
[TBL] [Abstract][Full Text] [Related]
10. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.
Ambrose PG; Drusano GL; Craig WA
Clin Infect Dis; 2012 Apr; 54 Suppl 3():S220-8. PubMed ID: 22431852
[TBL] [Abstract][Full Text] [Related]
11. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
Laohavaleeson S; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
[TBL] [Abstract][Full Text] [Related]
12. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.
Karlowsky JA; Walkty AJ; Baxter MR; Arhin FF; Moeck G; Adam HJ; Zhanel GG
Diagn Microbiol Infect Dis; 2017 Apr; 87(4):349-356. PubMed ID: 28159446
[TBL] [Abstract][Full Text] [Related]
14. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
15. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
Van Bambeke F
Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD; Sulaiman RM; Rybak MJ
Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin: a new option for the treatment of gram-positive infections.
Lin SW; Carver PL; DePestel DD
Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin resistance: are there better glycopeptides coming?
Linden PK
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
[TBL] [Abstract][Full Text] [Related]
19. Oritavancin: A Novel Lipoglycopeptide.
Mattox J; Belliveau P; Durand C
Consult Pharm; 2016 Feb; 31(2):86-95. PubMed ID: 26842686
[TBL] [Abstract][Full Text] [Related]
20. Oritavancin--an investigational glycopeptide antibiotic.
Ward KE; Mersfelder TL; LaPlante KL
Expert Opin Investig Drugs; 2006 Apr; 15(4):417-29. PubMed ID: 16548791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
